Literature DB >> 22882485

Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.

S Bavcar1, D J Argyle.   

Abstract

Tyrosine kinases (TKs) are key mediators of signalling pathways in cells. Located at the surface of the cell, within the cytoplasm or in the nucleous, TKs have been showed to be involved in regulation of normal cellular processes and also play an important role in the development, progression and spread of several types of cancer. Seventy percent of TK's are Receptor Tyrosine Kinases and these have become key targets for cancer therapy. This short synopsis is intended to give the reader an introduction to this area of targeted therapy for cancer as a prelude to this special edition of Veterinary and Comparative Oncology.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882485     DOI: 10.1111/j.1476-5829.2012.00342.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  7 in total

1.  Successful management of lymphangiosarcoma in a puppy using a tyrosine kinase inhibitor.

Authors:  Ji-Hyun Kim; Hakyoung Yoon; Hun-Young Yoon; Kidong Eom; Hyun-Jeong Sung; Jung-Hyun Kim
Journal:  Can Vet J       Date:  2018-04       Impact factor: 1.008

2.  IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach.

Authors:  Josef Singer; Erika Jensen-Jarolim
Journal:  J Carcinog Mutagen       Date:  2014-05-31

3.  Expression of platelet-derived growth factor receptor-α/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.

Authors:  Joong-Hyun Song; Do-Hyeon Yu; Tae-Sung Hwang; Byung-Joon Seung; Jung-Hyang Sur; Young Joo Kim; Dong-In Jung
Journal:  Vet Med Sci       Date:  2020-06-25

4.  Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines.

Authors:  Fulya Ustun-Alkan; Tülay Bakırel; Oya Üstüner; Ceren Anlas; Suzan Cinar; Funda Yıldırım; Aydın Gürel
Journal:  J Vet Res       Date:  2021-07-24       Impact factor: 1.744

5.  An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate Genes.

Authors:  Heike Thiemeyer; Leila Taher; Jan Torben Schille; Eva-Maria Packeiser; Lisa K Harder; Marion Hewicker-Trautwein; Bertram Brenig; Ekkehard Schütz; Julia Beck; Ingo Nolte; Hugo Murua Escobar
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

6.  Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.

Authors:  Charles H C Halsey; Daniel L Gustafson; Barbara J Rose; Amber Wolf-Ringwall; Robert C Burnett; Dawn L Duval; Anne C Avery; Douglas H Thamm
Journal:  BMC Vet Res       Date:  2014-05-06       Impact factor: 2.741

7.  Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.

Authors:  Milan Milovancev; Stuart C Helfand; Kevin Marley; Cheri P Goodall; Christiane V Löhr; Shay Bracha
Journal:  BMC Vet Res       Date:  2016-06-04       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.